| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Biochemistry |
Advanced Medicine East Inc., 8 Clarke Drive, Cranbury, NJ 08512, USA1
Author for correspondence: Eugene R. Baizman. Tel: +1 609 655 6925. Fax: +1 609 655 6930. e-mail: ebaizman{at}advmedicine.com
Moenomycin is a natural product glycolipid that inhibits the growth of a broad spectrum of Gram-positive bacteria. In Escherichia coli, moenomycin inhibits peptidoglycan synthesis at the transglycosylation stage, causes accumulation of cell-wall intermediates, and leads to lysis and cell death. However, unlike Esc. coli, where 5–6 log units of killing are observed, 0–2 log units of killing occurred when Gram-positive bacteria were treated with similar multiples of the MIC. In addition, bulk peptidoglycan synthesis in intact Gram-positive cells was resistant to the effects of moenomycin. In contrast, synthetic disaccharides based on the moenomycin disaccharide core structure were identified that were bactericidal to Gram-positive bacteria, inhibited cell-wall synthesis in intact cells, and were active on both sensitive and vancomycin-resistant enterococci. These disaccharide analogues do not inhibit the formation of N-acetylglucosamine-ß-1,4-MurNAc-pentapeptide-pyrophosphoryl-undecaprenol (lipid II), but do inhibit the polymerization of lipid II into peptidoglycan in Esc. coli. In addition, cell growth was required for bactericidal activity. The data indicate that synthetic disaccharide analogues of moenomycin inhibit cell-wall synthesis at the transglycosylation stage, and that their activity on Gram-positive bacteria differs from moenomycin due to differential targeting of the transglycosylation process. Inhibition of the transglycosylation process represents a promising approach to the design of new antibacterial agents active on drug-resistant bacteria.
Keywords: moenomycin, peptidoglycan synthesis, transglycosylation
a Present address: PanTherix Ltd, Unit 6.10, Kelvin Campus, Maryhill Rd, Glasgow G20 0SP, UK.
b Present address: Bristol-Myers Squibb Pharmaceutical Research Institute, PO Box 5100, Wallingford, CT 06392-7660, USA.
c Present address: National Institutes of Health, NIAID, DEA, Bethesda, MD 20892, USA.
This article has been cited by other articles:
|
|
 |
|
  T.-J. R. Cheng, M.-T. Sung, H.-Y. Liao, Y.-F. Chang, C.-W. Chen, C.-Y. Huang, L.-Y. Chou, Y.-D. Wu, Y.-H. Chen, Y.-S. E. Cheng, et al. Domain requirement of moenomycin binding to bifunctional transglycosylases and development of high-throughput discovery of antibiotics PNAS, January 15, 2008; 105(2): 431 - 436. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Terrak and M. Nguyen-Disteche Kinetic Characterization of the Monofunctional Glycosyltransferase from Staphylococcus aureus. J. Bacteriol., April 1, 2006; 188(7): 2528 - 2532. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Higgins, R. Chang, D. V. Debabov, J. Leung, T. Wu, K. M. Krause, E. Sandvik, J. M. Hubbard, K. Kaniga, D. E. Schmidt Jr., et al. Telavancin, a Multifunctional Lipoglycopeptide, Disrupts both Cell Wall Synthesis and Cell Membrane Integrity in Methicillin-Resistant Staphylococcus aureus Antimicrob. Agents Chemother., March 1, 2005; 49(3): 1127 - 1134. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Zervosen, W.-P. Lu, Z. Chen, R. E. White, T. P. Demuth Jr., and J.-M. Frere Interactions between Penicillin-Binding Proteins (PBPs) and Two Novel Classes of PBP Inhibitors, Arylalkylidene Rhodanines and Arylalkylidene Iminothiazolidin-4-ones Antimicrob. Agents Chemother., March 1, 2004; 48(3): 961 - 969. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |
